Published in Nat Rev Urol on May 28, 2013
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer | NCT01558427
PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. Eur J Nucl Med Mol Imaging (2017) 0.78
Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment. Radiat Oncol (2016) 0.78
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol (2006) 5.20
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys (2007) 3.87
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol (2003) 3.73
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol (2007) 2.86
Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys (2011) 2.86
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (1994) 2.53
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol (2008) 2.19
Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer (2012) 2.15
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.92
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging (2010) 1.85
Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.79
Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys (2007) 1.77
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging (2009) 1.71
Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging (2009) 1.66
Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology (1994) 1.64
The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol (2010) 1.61
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys (2006) 1.60
Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer (2001) 1.58
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology (2010) 1.50
18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis (2011) 1.50
Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg (2007) 1.43
[18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int (2010) 1.43
Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology (2009) 1.34
Role of lymphography in carcinoma of the prostate. Br Med J (1975) 1.34
Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med (2003) 1.32
Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol (2012) 1.26
Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.26
Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med (2008) 1.23
Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol (2010) 1.22
Prostate-specific membrane antigen-based imaging. Urol Oncol (2012) 1.22
Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology (2010) 1.12
Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol (1996) 1.12
Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol (2004) 1.08
Diffusion-weighted imaging in head and neck cancers. Future Oncol (2009) 1.08
Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys (2010) 1.07
Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. Radiother Oncol (2010) 1.07
Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate (2009) 1.05
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol (2011) 1.04
Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys (2009) 1.03
Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys (2009) 1.03
Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol (2010) 1.02
Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology (1999) 1.01
Lymphatic drainage patterns from the treated breast. Ann Surg Oncol (2009) 0.99
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging (2009) 0.98
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology (1999) 0.97
Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis (2002) 0.96
Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.96
Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (1998) 0.95
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging (2010) 0.95
Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys (1988) 0.94
Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol (2007) 0.94
PET/CT in prostate cancer: non-choline radiopharmaceuticals. Q J Nucl Med Mol Imaging (2012) 0.90
Value of SPECT/CT for detection and anatomic localization of sentinel lymph nodes before laparoscopic sentinel node lymphadenectomy in prostate carcinoma. J Nucl Med (2009) 0.90
PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med (2012) 0.90
Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 0.90
Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiother Oncol (2012) 0.89
Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys (2005) 0.88
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med (2011) 0.88
Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Radiat Oncol Biol Phys (2012) 0.87
Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys (2011) 0.87
Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int (2003) 0.85
Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med (2007) 0.85
Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.85
Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol (2004) 0.83
Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol (2001) 0.82
Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) (2012) 0.82
PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys (1994) 0.82
High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys (2011) 0.81
Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer (2004) 0.81
The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol (2006) 0.80
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol (2009) 0.80
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys (2009) 0.80
Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys (1996) 0.79
Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.77
Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys (2002) 0.77
Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases. Eur J Surg Oncol (2008) 0.76
Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Int J Radiat Oncol Biol Phys (2012) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol (2009) 2.84
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol (2004) 2.82
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Label fusion in atlas-based segmentation using a selective and iterative method for performance level estimation (SIMPLE). IEEE Trans Med Imaging (2010) 2.71
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Automatic segmentation of the prostate in 3D MR images by atlas matching using localized mutual information. Med Phys (2008) 2.46
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology (2003) 2.31
Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol (2011) 2.30
The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology (2013) 2.19
Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol (2008) 2.17
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol (2006) 2.14
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging (2013) 2.13
A case of abiraterone acetate withdrawal. Eur Urol (2013) 2.06
Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res (2012) 1.83
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
MRI/linac integration. Radiother Oncol (2007) 1.81
Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80
Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol (2014) 1.77
18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med (2006) 1.75
Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys (2007) 1.73
Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71
Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol (2003) 1.69
18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol (2012) 1.66
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol (2010) 1.63
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61
99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging (2012) 1.57
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55
F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med (2009) 1.55
PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol (2010) 1.55